For the first time, INCATE’s Selection Committee didn’t simply meet — they came together in person at the headquarters of one of our industry partners, creating an atmosphere in Munich filled with energy, curiosity, and a shared commitment to innovation.

What began as a session to evaluate new ventures quickly evolved into something much bigger: meaningful discussions about the future of antimicrobial therapies, the challenges still facing the field, and the breakthroughs needed to move innovation forward.

We would like to extend a special thank you to MSD Germany for hosting this important gathering, and to all Selection Committee members — both those who traveled from across Europe and beyond, and those who joined remotely — for their dedication, expertise, and enthusiasm. Their commitment is what continues to make the INCATE community so impactful.

Following this inspiring meeting, the ventures awarded Stage I were:

– Affirma Biotech
– Astralytix
– i-seq Biotechnology
– TU Berlin
– University of Auckland – A Novel Anti-virulence Vaccine for Staphylococcal Infection
– Università di Pavia

Congratulations to all the selected teams!

Learn more about all the ventures awarded Stage I in previous INCATE selection rounds HERE.